Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Theranos

Theranos
2003 FOUNDED
OOB STATUS
51-60 EMPLOYEES
Liquidation LATEST DEAL TYPE
Description

Developer of bio-monitoring systems designed to facilitate small-sample collection, testing and rapid communication of diagnostic information.The company's proprietary miniLab created an integrated infrastructure for real-time testing, decision making and individualized therapy, enabling laboratories to process early detection and intervention.

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Monitoring Equipment
Primary Office
  • 1701 Page Mill Road
  • Palo Alto, CA 94304
  • United States
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Theranos’s full profile, request a free trial.

Theranos Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Bankruptcy: Liquidation 05-Sep-2018 00000 Completed Out of Business
9. Debt - General 23-Dec-2017 00000 00000 Completed Generating Revenue/Not Profitable
8. Secondary Transaction - Private 27-Mar-2017 00000 Completed Generating Revenue/Not Profitable
7. Later Stage VC (Series C3) 01-Oct-2015 00000 000.00 Cancelled Generating Revenue/Not Profitable
6. Later Stage VC (Series C2) 04-Feb-2014 00000 00000 00.00 Completed Generating Revenue/Not Profitable
5. Later Stage VC (Series C1) 28-Mar-2013 0000 00000 00.000 Completed Generating Revenue/Not Profitable
4. Later Stage VC (Series C1) 08-Jul-2010 0000 000.00 00.000 Completed Generating Revenue/Not Profitable
3. Later Stage VC (Series C) 15-Nov-2006 000.00 000.00 00000 Completed Startup
2. Early Stage VC (Series B) 16-Feb-2006 $9.1M $16M 0000 Completed Startup
1. Early Stage VC (Series A) 30-Mar-2005 $6.95M $6.95M 000.00 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Theranos Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series C3 00,000,000 00.000000 000 000 00 000 0.000
Series C2 00,000,000 00.000000 000 000 00 000 00.000
Series C1 00,000,000 00.000000 00 00 00 00 0.000
Series C 00,000,000 00.000000 00.00 00.00 00 00.00 00.000
Series B 54,162,965 $0.000100 $0.18 $0.18 1x $0.18 10.03%
Series A 46,320,045 $0.000100 $0.15 $0.15 1x $0.15 8.58%
To view this company’s complete Cap Table, request access »

Theranos Executive Team (18)

Name Title Board
Seat
Contact
Info
Seth Michelson Ph.D Chief Scientific Officer & Principal Scientist, Biomathematician
Patrick O'Neill Chief Creative Officer
David Taylor Chief Executive Officer & General Counsel
Dave Wurtz Senior Vice President, Regulatory and Quality
Daniel Young Vice President

11 Former Executives

You’re viewing 5 of 18 executives. Get the full list »